Table 4.
Candidate solutes are presented according to the association of their plasma concentration (1/concentration0.7) with furosemide clearance (−log10[P]), separated by protein binding (>50% or ≤50%)
| Protein Binding | −log(P): Furosemide | −log(P): iGFR | Compound | Protein Binding (%) | CoV | CLr-to-CrCl Ratio |
|---|---|---|---|---|---|---|
| >50% | 8.2 | 5.7 | 4-Hydroxyphenylacetic acid | 50 | 0.2 | 1.3 |
| 6.4 | 5.8 | Kynurenic acid | 89 | 0.2 | 3.9 | |
| 5.2 | 4.3 | 2-Hydroxyphenylacetic acid | 54 | 0.3 | 1.2 | |
| 4.3 | 3.1 | Catechola | 65 | 0.7 | 0.6 | |
| ≤50% | 8.9 | 3.2 | Glucuronic acid | 7 | 0.2 | 1.9 |
| 8.8 | 5.6 | 2-[(4-Aminobenzoyl)amino]acetic acid | 19 | 0.3 | 10.9 | |
| 8.1 | 6.5 | 3-Methylcrotonylglycine | 17 | 0.3 | 10.7 | |
| 8.0 | 0.5 | 2-Dimethylamino-6-hydroxypurine | 15 | 0.2 | 12.6 | |
| 7.9 | 2.2 | S-Adenosyl-homocysteine | 31 | 0.2 | 2.5 | |
| 7.7 | 7.3 | 6′-Sialyl-N-acetyllactosamine | 17 | 0.2 | 4.6 | |
| 7.3 | 5.2 | 1,4-Cyclohexanedicarboxylic acid | 15 | 0.3 | 2.4 | |
| 7.2 | 5.7 | Galactonic acid | 16 | 0.5 | 0.8 | |
| 6.5 | 6.4 | Isoxanthopterin | 36 | 0.2 | 2.3 | |
| 6.4 | 5 | 3′-Sialyllactose | 21 | 0.3 | 5.7 | |
| 6.2 | 7.5 | Guanidinosuccinic acid | 5 | 0.2 | 6.6 | |
| 6 | 6.6 | 3-Methoxy-4-hydroxyphenylglycol sulfate | 18 | 0.2 | 8.2 | |
| 5.9 | 8.6 | Acetyl-L-threonine | 9 | 0.2 | 1.3 | |
| 5.9 | 1.6 | Mandelic acid | 44 | 0.3 | 1 | |
| 5.8 | 4 | 5-Fluoro-1-methyl-1H-1,3-benzodiazole | 22 | 0.2 | 9.6 | |
| 5.8 | 6.2 | Urea | 6 | 0.2 | 1 | |
| 5.7 | 3 | 4-Acetamidobutyric acid | 18 | 0.4 | 6.1 | |
| 5.6 | 7.4 | N2,N2-Dimethylguanosine | 29 | 0.2 | 5.3 | |
| 5.5 | 2.6 | Phenylacetylglycine | 18 | 0.3 | 4.3 | |
| 5.5 | 0.2 | Cholinea | 6 | 0.2 | 0.2 |
Only the top solutes reaching statistical significance by Bonferroni (0.05/528) are presented. iGFR, iohexol GFR; CoV, coefficient of variation; CLr-to-CrCl ratio, solute clearance-to-creatinine clearance ratio.
a
Did not also reach significance for penciclovir clearance.